
Transcatheter tricuspid valve intervention (TTVI) with various technologies is associated with lower mortality and clinical improvement, a new analysis of the TriValve Registry indicates.
The researchers, publishing in JACC Interventions, looked at mid-term data from the TriValve Registry, which included 312 high-risk patients with severe tricuspid regurgitation. Interventions, using a variety of technologies, targeted the leaflets, annulus, or coaptation and replacement. Implanted devices included the MitraClip, Trialign, TriCinch firs generation, caval valve implantation, FORMA, Cardioband, NaviGate, and PASCAL. Outcomes were determined prospectively at mid-term follow-up.
Mid-term 1-2 yr results from Intl TriValve Registry showed promising results w/ Transcath TV Interv (TTVI), 72% procedural success, 3.6% 30d mortality & 82% midterm survival: https://t.co/jAFLUDn03t #JACCINT pic.twitter.com/qtG2Ckw2Ax
— JACC Journals (@JACCJournals) January 23, 2019